OMPI Seminar: Ericka Venturina and Janos Szanto

Printer-friendly version
Date: 
Thursday, March 23, 2017

Time: Refreshments start at 3:15 pm. Seminar 3:30 - 5:00 pm

Location: NRC - 1200 Montreal Road, Building M-36 - Kelvin Room (please check in at the front desk).

 

1) "Modern implementation of dynamic conformal arc therapy"

 By Ericka Venturina, MSc student, Carleton University, Supervisor: Elsayed Ali.

Abstract: Dynamic Conformal Arc Therapy (DCAT) is an external beam radiation therapy modality that conforms the beam to the tumor while the linac head is rotating around the patient. The classical version of DCAT allows for only a single dose rate and no modulation. A modern implementation of DCAT features dose rate variation and modulation around the periphery of the target. These additional degrees of freedom make this modern implementation of DCAT closer to that of Volumetric Modulated Arc Therapy (VMAT) – a modality known for its ability to conform the radiation dose to the target and to carve it away from nearby healthy tissues. In this talk, I will present the methods and results of my characterization of this modern implementation of DCAT.

Based on this characterization, I will present the potential niches of DCAT in the current radiation therapy landscape in terms of planning efficiency, conformality, and robustness against machine and patient uncertainties.

 

2) "Clinical innovations of stereotactic radiotherapy in Ottawa"

By Janos Szanto, PhD, The Ottawa Hospital cancer Centre

Abstract: One of the first LINAC-based stereotactic radiotherapy in 1991 was established in Ottawa.  Shortly after, we developed a patient position monitoring system (PPMS) - a world first. Our successful stereotactic radiotherapy clinical program has been functional for more than 17 years.  CyberKnife entered a new era in 2010. Since then, we have had numerous clinical innovations: specialized imaging for trigeminal neuralgia or arteriovenous malformation (AVM); new fiducial application was evolved for liver lesions, prostate cancer treatments, etc; we also established a new patient-specific quality assurance program.